CD4 + T cells are central mediators of autoimmune pathology; however, defining their key
effector functions in specific autoimmune diseases remains challenging. Pathogenic CD4 + T …

Objective To examine the safety and pharmacokinetics of and clinical response to leflunomide,
a de novo pyrimidine synthesis inhibitor, when administered to patients with active …

Introduction Despite recent advances in anti-inflammatory therapy, rheumatoid arthritis (RA)
patients continue to rate pain as a priority. The etiology of RA pain is likely multifactorial, …

High-dimensional single-cell analyses have improved the ability to resolve complex mixtures
of cells from human disease samples; however, identifying disease-associated cell types or …

In a matter of weeks, the COVID-19 crisis has totally upended clinical medicine and the
practice of rheumatology. Our old ways of seeing patients in person, precepting fellows in clinic …

Objective. To ascertain the frequency of polymyalgia rheumatica (PMR) with a normal
erythrocyte sedimentation rate (ESR; ≤30 mm/hour) and to determine any defining clinical …

Diclofenac sodium, a phenylacetic acid—derived nonsteroidal anti-inflammatory drug (NSAID)
recently released in the United States, was associated with the development of significant …

The COPA syndrome is a monogenic, autoimmune lung and joint disorder first identified in
2015. This study sought to define the main pulmonary features of the COPA syndrome in an …

Objective To determine the effect of disclosure of rheumatoid arthritis ( RA ) risk personalized
with genetics, biomarkers, and lifestyle factors on health behavior intentions. Methods We …

Current therapies for systemic lupus erythematosus (SLE), a debilitating, potentially lethal,
multifactorial systemic autoimmune disease, are limited to suppressing disease activity and …